A High Titre “Spontaneous” Porcine FVIII Inhibitor

Thromb Haemost 1992; 68(04): 475-476
DOI: 10.1055/s-0038-1646300

Letters to the Editor

Schattauer GmbH Stuttgart

L P Clyne

Yale New Haven Hospital, New Haven, Connecticut, USA

,

A Levy

Yale New Haven Hospital, New Haven, Connecticut, USA

,

S Stein

Yale New Haven Hospital, New Haven, Connecticut, USA

,

P McPhedran

Yale New Haven Hospital, New Haven, Connecticut, USA

REFERENCES
1 Kernoff PBA. The clinical use of porcine factor VIII. In: Recent Advances in Hemophilia Care. Alan Liss Inc. 1990; pp 47-56
2 Ciavarella N, Antoncecchi S, Ranieri P. Efficacy of porcine factor VIII in the management of haemophiliacs with inhibitors. Br J Haematol 1984; 56: 641-648
3 Kernoff PBA, Thomas ND, Lilley KB, Matthews E, Goldman E, Tuddenham EGD. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 1984; 63: 31-41
4 Brettler DB, Forsberg AD, Levine PH. et al The use of porcine factor VIII concentrate (Hyate: C) in the treatment of patients with inhibitor antibodies to factor VIII: A multicenter U.S. experience. Arch Intern Med 1989; 149: 1381-1385
5 Hultin MB, Hennessey J. The use of polyelectrolyte-fractionated factor VIII in the treatment of a spontaneously acquired inhibitor to factor VIII. Thromb Res 1989; 55: 51-56
6 Hoyle CH, Ludlam CA. Acquired factor VIII inhibitor associated with multiple sclerosis, successfully treated with porcine factor VIII. Thromb Haemostas 1987; 57 (2) 233
7 Weston-Smith SG, Revell P, Lawrie AS, Holland LJ, Savidge GF. The rapid development of an IgM inhibitor of porcine factor VIII in a patient with acquired haemophilia. Br J Haematol 1990; 75: 434-436